Rigel presents promising data on R289 for lower-risk MDS patients at ASH: 33% achieved RBC-TI at doses ≥500 mg QD.
R289 is displaying good tolerance with elderly lower-risk MDS patients who have undergone extensive prior treatment. Preliminary efficacy has been noted at doses of 500 mg or higher once a day, where 33% (6 out of 18) of transfusion-dependent patients achieved RBC-TI. This success rate increased to 40%...
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments